Continued access to study treatment for current participants
Part of Cancer, Women’s health & pregnancy clinical trials.
This program lets people who are already doing well on a study treatment keep receiving it after the main study ends. It is only for those currently in the B2151009 study and benefiting from the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently in the B2151009 study and your doctor says the treatment is helping you.
- You have been following the study rules and are willing to keep doing so.
- Your disease has not gotten worse, according to your doctor.
- You agree to sign a consent form before continuing treatment.
- You are not pregnant or planning to become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment (GDC-4198) alone or with another drug (giredestrant) compared to a standard combination (abemaciclib and giredestrant) for people with advanced hormone receptor-positive, HER2-negative breast cancer that has progressed after previous treatments.
This trial lets people who were already in a related “parent” study either keep taking treatment or restart it after it had stopped working for a while. It’s meant for people who previously had a meaningful response and may still benefit from continued treatment.
This program provides access to two investigational drugs, balstilimab and zalifrelimab, for people who have already completed a related clinical trial. It aims to offer continued treatment options for those who may benefit.
This trial tests a new targeted therapy called gedatolisib for people with HR-positive, HER2-negative advanced breast cancer who have not yet received treatment for metastatic disease. It aims to see if adding this drug to standard hormone therapy can help control the cancer longer.
This study lets people who are already taking alpelisib in another Novartis trial keep getting it after that trial ends. It checks long-term safety and continued benefit.
This trial provides continued access to a Bicycle investigational product for people who are already benefiting from it in another Bicycle-sponsored study. It lets you keep receiving the treatment after your current study ends, as long as it is working and you are tolerating it.
Hear when a new Breast Neoplasm Malignant Female trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.